The ADVIA Centaur® XPT Immunoassay System is engineered for simplified, continuous operation and timely, trusted results.
"The ADVIA Centaur XPT System exceeded our expectations. Furthermore, we could reduce the monthly maintenance by 12 hours per year and operator maintenance time by 60%."
See how Labor Blackholm MVZ increased testing volume by 34% with 30% fewer analyzers
Anemia
Active B12
EPO
Ferritin
Folate
RBC Folate
Vitamin B12
Autoimmune
Anti-CCP IgG
Bone Metabolism
Intact PTH
Vitamin D Total
Cardiac
BNP
CKMB
High-Sensitivity Troponin I
Myoglobin
NT-proBNP
Diabetes
C-Peptide
Insulin
Growth
Growth Hormone hGH*
IGF-1*
IFBP-3*
Hepatitis
Anti-HBe2
Anti-HBs 2
HAV IgM
HAV Total
HBc IgM
HBc Total 2
HBeAg
HBsAg Confirmatory
HBsAg II
HBsAg II Quant
HCV
HIV
HIV Ag/Ab Combo (CHIV)
Immunosuppressant Drugs
Cyclosporine
Everolimus*
Sirolimus*
Tacrolimus*
Inflammation
IgE Total
IL-2*
IL-6
LBP
TNFα*
Liver Fibrosis
Enhanced Liver Fibrosis (ELF™) Test
HA (ELF™ Marker)
PIIINP (ELF™ Marker)
TIMP-1 (ELF™ Marker)
Metabolic
Cortisol
Homocysteine
Neurology
β-Amyloid 1-42(AB42)*
sNfL*
Total Tau (TTAU)*
Oncology
AFP
BR 27.29
CA 125II†
CA 15-3†
CA 19-9†
Calcitonin
CEA
Complexed PSA
CYFRA 21-1*
Free PSA
Neuron Specific Enolase (NSE)*
PSA
Serum HER-2/neu
Squamous Cell Carcinoma Antigen (SCC)*
Reproductive Endocrinology
AFP
Androstenedione
Anti-Müllerian Hormone
DHEA-SO4
Enhanced Estradiol
Free Beta HCG
FSH
hCG
LH
PAPP-A
PlGF
Progesterone
Prolactin
sFLT-1
SHBG
Testosterone II
Sepsis
Procalcitonin (PCT)
Special ID
EBV-EBNA IgG*
EBV-VCA IgG*
EBV-VCA IgM*
SARS-CoV-2 Ag (CoVAg)**
SARS-CoV-2 IgG (sCOVG)§
SARS-CoV-2 Total (COV2T)§
Syphilis
Zika Test‡
Therapeutic Drug Monitoring (TDM)
Carbamazepine
Digitoxin
Digoxin
Gentamicin
Phenobarbital
Phenytoin
Theophylline
Valproic Acid
Vancomycin
Thyroid
aTgII
Anti-TPO
Free T3
Free T4
Total T3
Total T4
TSH3-Ultra
TSH
T Uptake
ToRCH
CMV IgG
CMV IgM
Herpes-1 IgG
Herpes-2 IgG
Rubella IgG II
Rubella IgM
Toxoplasma IgG
Toxoplasma IgM
Download ADVIA Centaur XPT System Technical Specifications
* Under development. Not available for sale.
† CA 125II , CA 19-9 and CA 15-3 are trademarks of Fujirebio Diagnostics, Inc.
‡ Limited distribution
§ This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary by country.
** This test has not been reviewed by the FDA. In the US, use of this test is limited to laboratories that are certified under Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high-complexity testing. Product availability may vary by country and is subject to regulatory requirements.
The outcomes achieved by the Siemens Healthineers customers described herein were achieved in each customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of ITadoption) there can be no guarantee that others will achieve the same results.
The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.
